Epigral Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹4,751 Cr
- Book Value
- ₹515.00
- Stock P/E
- 17.53
- Dividend Yield
- 0.45%
- ROE
- 16.00%
- ROCE
- 15.30%
- PEG Ratio
- —
- EV/EBITDA
- —
Fundamentals from Screener.in, as of 6 Aug 2026. Live price via Yahoo Finance.
Epigral share price today
Epigral Ltd (NSE: EPIGRAL), formerly Meghmani Finechem, has evolved from a chlor-alkali producer into an integrated chemicals platform. Chlorine and caustic soda remain the foundation, but the investment case increasingly depends on converting captive chlorine into chloromethanes, hydrogen peroxide, CPVC resin and compound, epichlorohydrin and chlorotoluene-chain products. Higher-value derivatives can improve mix; they also require capital, customer qualification and careful execution through a chemical cycle.
Gale’s internal 6 August 2026 snapshot stored a price of ₹1,101.20 and market capitalisation of ₹4,751 crore. The universe row was sparse and had no valuation or thesis decision. We therefore omit a rating and paid buy range rather than inventing one. The article supplements the fixed snapshot with the company’s Q1 FY27 materials and current Screener financials, clearly separating the two dates.
Integration is the core strategic advantage
Chlor-alkali electrolysis produces caustic soda, chlorine and hydrogen. Caustic soda is widely traded and cyclical; chlorine is difficult and costly to transport over long distances. A producer that converts chlorine on site into value-added derivatives can reduce disposal risk, diversify revenue and capture more value from the same molecule.
| Value-chain layer | Key products | Strategic role | Main risk |
|---|---|---|---|
| Chlor-alkali | Caustic soda and chlorine | Base scale and captive feedstock | Commodity cycle and power cost |
| Inorganic derivative | Hydrogen peroxide | Broad industrial application | Capacity additions and price pressure |
| Chloromethanes | Methylene dichloride, chloroform and related products | Captive chlorine conversion | End-market and import competition |
| Polymer chain | CPVC resin and CPVC compound | Import substitution and building-material demand | Qualification, technology and housing cycle |
| Advanced derivatives | Epichlorohydrin and chlorotoluenes | Higher-value specialty mix | Ramp-up, feedstock and customer concentration |
The moat is not merely owning many plants. It is balancing molecules, utilities and demand so one product does not become a bottleneck. Integration improves economics only when plants run reliably and derivatives earn an adequate spread.
Electricity reliability and planned maintenance are part of that balance. Chlor-alkali is power intensive, while downstream units need a steady flow of captive intermediates. A shutdown in one link can reduce utilisation across the chain even when demand is healthy. Investors should separate temporary maintenance effects from weaker structural spreads and check whether lost production is recovered without compromising safety or customer service.
Q1 FY27 showed volume and margin recovery
The June 2026 quarter produced consolidated sales of about ₹705 crore, operating profit of ₹179 crore and net profit of ₹100 crore in Screener’s updated table. Revenue was above the prior quarter and year earlier, while the operating margin recovered to 25% from 17% in Q3 FY26 and 23% in Q4.
| Consolidated measure, ₹ crore | Q1 FY26 | Q4 FY26 | Q1 FY27 | Reading |
|---|---|---|---|---|
| Sales | 607 | 736 | 705 | +16% YoY; lower sequentially after a strong Q4 |
| Operating profit | 163 | 168 | 179 | Improved against both comparisons |
| Operating margin | 27% | 23% | 25% | Partial margin recovery |
| Interest | 23 | 16 | 7 | Lower finance burden |
| Depreciation | 42 | 42 | 43 | Large installed asset base |
| Profit before tax | 107 | 110 | 134 | Strong operating and finance-cost bridge |
| Net profit | 161 | 81 | 100 | Prior-year PAT distorted by a tax credit |
| EPS | ₹37.25 | ₹18.76 | ₹23.12 | Q1 growth must be judged against normalized earnings |
The Q1 FY26 PAT comparison is misleading because that quarter carried a negative effective tax rate. Operating profit and PBT provide a cleaner year-on-year reading. Our scenario base uses normalized TTM EPS, not the tax-distorted high.
Derivatives and specialties now drive the quality debate
Epigral’s derivatives and specialty chemicals contributed about 52% of FY26 revenue, up from roughly 25% in FY22. A larger share can reduce direct exposure to caustic-soda prices and support better customer relationships. It also makes the portfolio more complex.
| Mix question | Constructive evidence | Warning evidence |
|---|---|---|
| Is specialty share rising profitably? | Contribution and cash margin rise with revenue mix | New products add sales but dilute return on capital |
| Is chlorine balanced? | More captive conversion with stable plant rates | One derivative bottlenecks the chain |
| Are products qualified? | Repeat contracts across diverse customers | Ramp relies on spot sales or discounting |
| Is pricing resilient? | Spreads hold despite industry capacity | Imports or domestic additions compress realisation |
| Is disclosure adequate? | Volumes and economics are reported consistently | Portfolio breadth obscures weak products |
Mix should be assessed through margins and ROCE, not percentage of revenue alone. A specialty label cannot protect an undifferentiated molecule from overcapacity.
CPVC resin and compound offer import-substitution potential
CPVC is used in hot- and cold-water plumbing, fire systems and industrial applications. India has historically depended on imported resin technology and supply. Domestic production can shorten supply chains and support pipe makers, provided quality is consistent and formulations pass lengthy customer tests.
Epigral’s position across resin and compound creates a route to capture more of the chain. The risk is that global suppliers or new domestic plants create price competition before utilisation matures. Investors should follow certified customers, plant utilisation and contribution—not only announced capacity.
Epichlorohydrin links integration with a new cycle
Epichlorohydrin is used principally in epoxy resins and related applications. Its demand connects Epigral to construction, coatings, wind energy, electronics and industrial activity. The project broadens the portfolio, but product spreads can be volatile and imports provide a price benchmark.
The plant’s value depends on stable feedstock, operating rates and customer acceptance. A newly commissioned specialty asset can look attractive at peak spreads and disappointing at trough spreads. The multi-year model therefore assumes moderate EPS growth rather than immediate full-capacity economics.
Chlor-alkali remains exposed to power and commodity prices
Electricity is a major input to electrolysis. Captive renewable power and energy efficiency can reduce cost and carbon intensity, but cannot remove price cycles. Caustic-soda realisation responds to domestic supply, imports, freight and demand from alumina, textiles, paper, detergents and chemicals.
| Chlor-alkali driver | Positive condition | Negative condition |
|---|---|---|
| Caustic price | Balanced capacity and firm industrial demand | Imports or new plants create oversupply |
| Power cost | High captive renewable availability | Grid tariffs or fuel cost rise |
| Chlorine balance | Derivatives consume more captive output | Downstream outages force discounting |
| Plant utilisation | Reliable operation near design rate | Maintenance or commissioning interruptions |
| Logistics | Regional demand absorbs output | Freight makes distant sales uneconomic |
An integrated producer can outperform a standalone commodity plant, but base chemistry still affects the cost and opportunity set of every derivative.
FY26 revenue held while profitability reset
FY26 consolidated sales were ₹2,527 crore, nearly flat with FY25’s ₹2,550 crore. Operating profit fell from ₹711 crore to ₹566 crore and margin from 28% to 22%. Net profit declined from ₹358 crore to ₹332 crore, with tax effects making the bottom-line comparison less clean than operating profit.
| Consolidated measure, ₹ crore | FY25 | FY26 | Change |
|---|---|---|---|
| Sales | 2,550 | 2,527 | Broadly flat |
| Operating profit | 711 | 566 | -20% approximately |
| Operating margin | 28% | 22% | Six-point decline |
| Interest | 53 | 72 | Higher despite year-end debt reduction |
| Depreciation | 133 | 168 | New capacity burden |
| Profit before tax | 541 | 341 | Significant operating reset |
| Net profit | 358 | 332 | Supported by a low effective tax rate |
| Reported EPS | ₹82.91 | ₹76.95 | Not a clean recurring comparison |
The weak PBT bridge is a warning against using reported FY26 EPS without normalisation. Q1 FY27 suggests improvement, but one quarter cannot establish the through-cycle earnings base.
Debt reduced, while capital intensity remains high
Borrowings declined from ₹964 crore in FY24 to ₹572 crore in FY26, even as the company invested in new products. Lower Q1 interest is encouraging. The balance sheet still carries a large fixed-asset and work-in-progress base, so depreciation and maintenance capital will remain material.
| Balance-sheet measure, ₹ crore | FY24 | FY25 | FY26 |
|---|---|---|---|
| Equity and reserves | 1,255 | 1,904 | 2,221 |
| Borrowings | 964 | 593 | 572 |
| Fixed assets | 1,767 | 2,238 | 2,117 |
| Capital work in progress | 483 | 64 | 451 |
| Other assets | 524 | 752 | 915 |
| Total assets | 2,794 | 3,152 | 3,505 |
CWIP rising to ₹451 crore indicates another investment phase. Returns depend on timely commissioning and utilisation. Debt reduction is valuable only if new plants do not require a renewed borrowing cycle before producing cash.
Cash flow must fund the next stage
Cash from operations was ₹436 crore in FY26, close to the prior year’s ₹441 crore and equal to about 90% of operating profit. Investing cash outflow was ₹355 crore, leaving reported free cash flow of roughly ₹50 crore.
| Cash-flow or working-capital item | FY25 | FY26 | Reading |
|---|---|---|---|
| Cash from operations | ₹441 Cr | ₹436 Cr | Stable despite lower profit |
| Investing cash flow | -₹262 Cr | -₹355 Cr | Larger investment phase |
| Free cash flow | ₹254 Cr | ₹50 Cr | Lower after capex |
| Debtor days | 33 | 60 | Receivables expanded |
| Inventory days | 105 | 89 | Some inventory improvement |
| Cash-conversion cycle | 88 days | 83 days | Slightly better overall |
The rise in debtor days deserves attention because new products can require commercial credit during ramp-up. Sustainable specialty economics should eventually improve cash conversion, not merely gross margin.
Environmental and process safety are valuation variables
Chlorine, epichlorohydrin and other chemicals require rigorous containment, maintenance and emergency systems. An incident can stop production, harm people, trigger remediation and damage customer confidence. Compliance expenditure is therefore part of normal economics, not a discretionary overhead.
Water availability, effluent treatment and renewable-power claims also matter. Investors should read environmental disclosures alongside financial reports and avoid treating absence of a recent incident as proof of zero risk.
Gale’s 6 August valuation snapshot
| Snapshot metric | Value used | Interpretation |
|---|---|---|
| Share price | ₹1,101.20 | Fixed model cutoff |
| Market capitalisation | ₹4,751 Cr | Micro-cap band in Gale’s universe |
| Normalized P/E | About 17.5× | Moderate if earnings are genuinely recurring |
| Book value per share | About ₹515 | Reflects a capital-intensive asset base |
| ROE | About 16.0% | Healthy, aided by tax mix in recent periods |
| ROCE | 15.3% | Needs improvement from new projects |
| Dividend yield | About 0.45% | Small part of expected return |
| Normalized snapshot TTM EPS | ₹62.82 | Scenario starting base |
The stock was 41.8% below the stored 52-week high. That decline reflects the earnings reset and chemical-cycle risk; it is not automatically a bargain.
Valuation framework: normalize tax and spreads
We compound ₹62.82 of normalized TTM EPS and apply an exit P/E. The 2026 target uses 147/365 of the annual growth assumption from 6 August 2026; each later target adds one full year. Values are rounded to the nearest ₹5 and exclude dividends.
| Scenario | Annual EPS growth | Exit P/E | Operating interpretation |
|---|---|---|---|
| Bear | 4% | 13× | Chemical spreads remain soft and new assets earn modest returns |
| Base | 10% | 18× | Derivative mix grows, Q1 recovery holds and debt stays controlled |
| Bull | 16% | 23× | CPVC and advanced derivatives ramp with stronger margins and ROCE |
The assumptions do not restore peak margins automatically. The bull case needs successful utilisation and cash conversion, while the bear case shows the effect of a prolonged but survivable downcycle.
Epigral share price target 2026 to 2030
The gated table is a set of sensitivities, not a promise. Commodity prices, power, plant reliability, taxation and capacity additions can move outside the model. Gale has not assigned an internal rating or paid valuation range to this sparse database row; this article does not imply one.
What would change the thesis
The case would strengthen if derivatives exceed half of revenue with improving cash margin, CPVC and epichlorohydrin utilisation rises, Q1’s lower finance cost persists and ROCE recovers. Stable operating tax and clear volume disclosure would improve confidence in normalized EPS.
It would weaken if new domestic supply compresses spreads, plant outages disrupt the chlorine balance, receivables remain elevated or CWIP commissions late. A return to heavy borrowing before projects generate cash would also alter the base case.
Quarterly monitoring scorecard
| Question | Constructive evidence | Warning evidence |
|---|---|---|
| Is mix improving? | Derivatives grow with stable or higher margin | Specialty share rises while ROCE falls |
| Are plants executing? | High utilisation and reliable commissioning | Outages, delays or repeated trial costs |
| Is the base cycle supportive? | Caustic spreads and power costs stabilise | Oversupply compresses the chain |
| Is growth funded internally? | CFO covers capex and debt declines | New CWIP requires another leverage cycle |
| Are profits recurring? | Normal tax and cash track PBT | Tax credits or other items dominate PAT |
Should you buy Epigral at the current price?
Epigral offers real integration, a growing derivative portfolio, lower leverage than two years ago and a valuation that is less demanding than many specialty chemical peers. It also remains cyclical, capital intensive and exposed to project execution. The discount from the high is evidence of risk, not proof of value.
Investors should compare the bear case with their required return, then demand evidence from utilisation, cash flow and normalized tax. No rating or buy range has been invented while Gale’s internal review remains incomplete.
FAQ
What is the Epigral share price target for 2030?
The signed-in table shows bear, base and bull outcomes from normalized EPS and exit P/E assumptions. The range reflects different chemical-cycle and execution outcomes rather than one certain forecast.
Why does Epigral convert chlorine into derivatives?
Chlorine is difficult to transport economically. Captive conversion can balance the chlor-alkali plant, diversify products and capture more value from the same feedstock.
Why use ₹62.82 as normalized TTM EPS?
It reflects the current trailing operating base after removing reliance on the tax-distorted Q1 FY26 comparison. It is more conservative than peak reported EPS.
What is Epigral’s main growth opportunity?
Higher utilisation and customer adoption in CPVC, epichlorohydrin, chloromethanes and the chlorotoluenes chain could raise the derivative share and capital returns.
What is the biggest risk?
Chemical spreads and plant execution can interact. Weak pricing during a heavy capex phase can depress utilisation, cash flow and valuation at the same time.
When will Epigral report next?
Check Gale’s results calendar and verify the board-meeting date in Epigral’s exchange filing.
Related research
- PI Industries share price target
- Himadri Speciality Chemical share price target
- Acutaas Chemicals share price target
Sources and methodology
- Epigral Q1 FY27 investor presentation filed with BSE
- Epigral official quarterly-results and annual-report archive
- Epigral corporate website
- Epigral consolidated financials on Screener
The fixed price and market value are from Gale’s approved 6 August Screener capture. The sparse record was supplemented with the Q1 company filing and updated consolidated Screener table; the normalized EPS base is labelled rather than presented as stored fact. Yahoo Finance supplies only the live quote.
This article is research and education, not personalised investment advice or a recommendation to transact. Gale is not a SEBI-registered investment adviser. Price targets are scenario arithmetic, not promises. Verify current spreads, filings and project status, and consult a registered adviser before acting.